Site Map

Home
Home Page

Blood Safety & Pathogen Inactivation
Blood Safety & Pathogen Inactivation
Bacteria
New & Emerging Pathogens
Other Known Pathogens
Window Period Limitation
Leukocytes

Product Overview
ONE System - Two Components
INTERCEPT Platelets
INTERCEPT Plasma
Safety & Hemovigilance
Amotosalen Mechanism of Action
INTERCEPT Process Video

Resource Center
Resource Overview
Instructions & Manuals
Technical Data Sheets
INTERCEPT Platelets
:: Product Description
:: Indications & Contraindications
:: Viruses
:: Bacteria
:: Parasites
:: Leukocytes
:: Clinical Use
INTERCEPT Plasma
:: Product Description
:: Indications & Contraindications
:: Viruses
:: Bacteria
:: Parasites
:: Leukocytes
:: Clinical Use
Customer Letters
CE Mark & ISO Certificates
Scientific Publications
:: Recent Publications
:: Blood Safety & PI
:: INTERCEPT Platelets - Journal Articles
:: INTERCEPT Platelets - Conf. Abstracts
:: INTERCEPT Plasma - Journal Articles
:: INTERCEPT Plasma - Conf. Abstracts

INTERCEPT in Use
INTERCEPT Usage Overview
Customer Case Studies
    :: Sweden - Uppsala University Hospital
    :: Belgium - BTC Mont-Godinne
    :: Spain - Spanish Red Cross
Customer Profiles
    :: Slovenia - Blood Transfusion Center of Slovenia

News & Events
Recent News & Upcoming Events
Webinar Series
    :: Active Hemovigilance Results for INTERCEPT
    :: RBC Component Viability Requirements
    :: Pandemic & Emerging Pathogens
    :: 3- & 5-year INTERCEPT Experiences
    :: Clinical Trials in Transfusion Medicine
    :: Plasma: INTERCEPT vs Quarantine (German)
    :: Blood Safety in the Age of PI (Spanish)
Symposium Webcasts
    :: ISBT Berlin 2010 Symposium
    :: AABB New Orleans 2009 Workshop
    :: EHS Rome 2009 Symposium
    :: AABB Montreal 2008 Workshop
    :: ISBT Macao 2008 Symposium

Contact Us
About Cerus
Legal
Privacy Policy

 
© Cerus Corporation. All Rights Reserved.

Use of the INTERCEPT Blood System in the United States is limited by Federal law to investigational use. If you are a resident of the U.S., please click here.

The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located. The INTERCEPT Blood System is CE marked for use with platelets and plasma. No pathogen inactivation system has been shown to inactivate all pathogens.

Website design by NetPilot Web Solutions
Legal Info  |   Privacy Policy